The safety and feasibility of inhaled amikacin for treatment of refractory chronic lower respiratory tract infections

The safety and feasibility of inhaled amikacin for treatment of refractory chronic lower respiratory tract infections - Inhaled amikacin for treatment of refractory chronic lower respiratory tract infections

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000017874

Enrollment

Registered

2015-06-11

Start date

2013-11-06

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic lower respiratory tract infections

Interventions

Inhaled amikacin therapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The study population consisted of the patients with refractory chronic lower respiratory tract infections, such as nontuberculous mycobacterial lung disease, who attended a university hospital as outpatients.

Exclusion criteria

Exclusion criteria: Drug allergy of amikacin

Design outcomes

Primary

Measure	Time frame
Microbiological examination from lower respiratory tract specimens, Clinical symptoms, Radiological examination, Adverse events	—

Countries

Japan

Contacts

Public ContactNaoki Hasegawa

Keio University School of Medicine Center for Infectious Diseases and Infection Control

n-hasegawa@z8.keio.jp0333531211

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026